Trial
NCT04784520
A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Collaborators
—
Condition
Biliary Tract Cancer
Intervention
HA121-28 tablets
Why stopped
The primary endpoint did not meet expectation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-06